REDMILE GROUP LLC
Q4 2023 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001425738
· CRD 143606
· SEC-registered investment adviser
$2.8B Reported Value Total
REDMILE GROUP reports 27 total accounts under management (AUM). There are 27 discretionary accounts valued at $6,473,965,022, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
27 funds
· $7.7B gross asset value
Hedge Fund: $5.4B · Venture Capital Fund: $1.2B · Private Equity Fund: $1.1B
Source: Form ADV filed 2026-08-28
Reported value
$2.8B
Quarter over quarter
+29.1%
Holdings
70
Top-10 concentration
54.3%
Key People
Form ADV owners & control persons
Jeremy Charles Green
MANAGING MEMBER
Michael Stewart Lee
MANAGING DIRECTOR
Bryan Ranney Crapo
CHIEF OPERATING OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q4 2023 13F record
Q4 2023 13F filing summary
| Period of report | December 31, 2023 |
|---|---|
| Filed | February 14, 2024 |
| Form | 13F-HR |
| Reported value | $2.8B |
| Positions | 70 |
| Change in reported value | +33.0% |
| New positions | 9 |
| Exited positions | 7 |
| Position turnover | 20.8% |
| Top-10 concentration | 54.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
39 | $1.5B |
|
Q1 2026 13F
Filed May 15, 2026
|
35 | $1.5B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
34 | $1.4B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
40 | $1.0B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
48 | $939.6M |
|
Q1 2025 13F
Filed May 15, 2025
|
56 | $1.1B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
62 | $1.4B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
63 | $1.7B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
63 | $1.7B |
|
Q1 2024 13F
Filed May 15, 2024
|
77 | $2.7B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
70 | $2.8B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
68 | $2.1B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
72 | $2.6B |
|
Q1 2023 13F
Filed May 15, 2023
|
76 | $2.3B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
69 | $2.4B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
70 | $2.6B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
71 | $2.6B |
|
Q1 2022 13F
Filed May 16, 2022
|
70 | $3.2B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
71 | $4.4B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
75 | $5.7B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | IMGN IMMUNOGEN INC | $487.0M | 17.42% |
| 2 | KRYS KRYSTAL BIOTECH INC | $215.0M | 7.69% |
| 3 | FOLD AMICUS THERAPEUTICS INC | $210.4M | 7.53% |
| 4 | SRRK SCHOLAR ROCK HLDG CORP | $120.4M | 4.31% |
| 5 | RYZB RAYZEBIO INC | $115.5M | 4.13% |
| 6 | AUGX AUGMEDIX INC | $95.8M | 3.43% |
| 7 | DCPH DECIPHERA PHARMACEUTICALS IN | $77.4M | 2.77% |
| 8 | SPY SPDR S&P 500 ETF TR | $67.7M | 2.42% |
| 9 | RGNX REGENXBIO INC | $67.5M | 2.41% |
| 10 | BHVN BIOHAVEN LTD | $61.8M | 2.21% |
| 11 | ZYME ZYMEWORKS INC | $60.2M | 2.15% |
| 12 | LIVN LIVANOVA PLC | $58.8M | 2.1% |
| 13 | ALXO ALX ONCOLOGY HLDGS INC | $54.5M | 1.95% |
| 14 | CTLT CATALENT INC | $49.4M | 1.77% |
| 15 | FATE FATE THERAPEUTICS INC | $49.3M | 1.76% |
| 16 | PLRX PLIANT THERAPEUTICS INC | $48.8M | 1.75% |
| 17 | KYMR KYMERA THERAPEUTICS INC | $46.4M | 1.66% |
| 18 | IMNM IMMUNOME INC | $41.5M | 1.48% |
| 19 | IMVT IMMUNOVANT INC | $41.2M | 1.47% |
| 20 | BSX BOSTON SCIENTIFIC CORP | $40.1M | 1.43% |
Values as reported on the Q4 2023 Form 13F. Every position is in the holdings table below.